Bausch + Lomb Corporation (BLCO)

19.47 +0.35 (+1.83%) At close: 04:00PM EDT

Bausch + Lomb Corporation

520 Applewood Crescent
Vaughan, ON L4K 4B4
Canada
(905) 695-7700
https://www.bausch.com

Sector(s): Healthcare
Industry: Medical Instruments & Supplies
Full-time employees: 13,000

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Brenton L. Saunders J.D.	CEO & Chairman	10.13M	N/A	1970
Mr. Osama A. Eldessouky	Executive VP & CFO	1.32M	N/A	1972
Mr. A. Robert D. Bailey	Executive VP & Chief Legal Officer	1.16M	N/A	1963
Dr. Yehia Hashad M.D.	Executive VP of Research & Development and Chief Medical officer	1.23M	N/A	1968
Mr. Andrew Stewart	President of Global Pharmaceuticals & International Consumer	1.37M	N/A	1975
Mr. Alan Waterhouse CPFA, MBA	Executive VP and Chief Supply Chain & Operations Officer	N/A	N/A	1960
Mr. Frederick J. Munsch	Senior VP, Controller & Chief Accounting Officer	N/A	N/A	1971
Mr. Jonathon L. Kellerman	Chief Compliance Officer	N/A	N/A	N/A
T.J. Crawford	Chief Communications Officer	N/A	N/A	N/A
Dr. Manisha A. Narasimhan Ph.D.	Chief Corporate Development & Digital Officer	N/A	N/A	1977

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

Corporate governance

Bausch + Lomb Corporation’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.